- Home
- CLLS vs TEI Comparison
CLLS vs TEI Comparison
Compare CLLS & TEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- TEI
- Stock Information
- Founded
- CLLS 1999
- TEI 1993
- Country
- CLLS France
- TEI United States
- Employees
- CLLS N/A
- TEI N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- TEI Finance Companies
- Sector
- CLLS Health Care
- TEI Finance
- Exchange
- CLLS Nasdaq
- TEI Nasdaq
- Market Cap
- CLLS 299.0M
- TEI 282.9M
- IPO Year
- CLLS 2007
- TEI N/A
- Fundamental
- Price
- CLLS $2.85
- TEI $6.05
- Analyst Decision
- CLLS Buy
- TEI
- Analyst Count
- CLLS 1
- TEI 0
- Target Price
- CLLS $4.00
- TEI N/A
- AVG Volume (30 Days)
- CLLS 199.3K
- TEI 142.4K
- Earning Date
- CLLS 08-04-2025
- TEI 01-01-0001
- Dividend Yield
- CLLS N/A
- TEI 10.51%
- EPS Growth
- CLLS N/A
- TEI N/A
- EPS
- CLLS N/A
- TEI N/A
- Revenue
- CLLS $63,438,000.00
- TEI N/A
- Revenue This Year
- CLLS N/A
- TEI N/A
- Revenue Next Year
- CLLS $4.90
- TEI N/A
- P/E Ratio
- CLLS N/A
- TEI N/A
- Revenue Growth
- CLLS 223.09
- TEI N/A
- 52 Week Low
- CLLS $1.10
- TEI $4.35
- 52 Week High
- CLLS $3.24
- TEI $5.39
- Technical
- Relative Strength Index (RSI)
- CLLS 59.27
- TEI 55.04
- Support Level
- CLLS $2.71
- TEI $5.95
- Resistance Level
- CLLS $3.08
- TEI $6.13
- Average True Range (ATR)
- CLLS 0.20
- TEI 0.06
- MACD
- CLLS -0.03
- TEI -0.01
- Stochastic Oscillator
- CLLS 61.67
- TEI 55.56
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About TEI Templeton Emerging Markets Income Fund Inc.
Templeton Emerging Markets Income Fund is a closed-end fund. It seeks high, current income, with a secondary goal of capital appreciation, by investing, under normal market conditions. The company's investment portfolio includes Foreign Government and Agency Securities; Quasi-Sovereign and Corporate Bonds; Common Stocks and Other Equity Interests, and Short-Term Investments, and Money Market Funds.